Dr Matt Huentelman
Boosting ABCC1 could lessen the production of plaque linked to Alzheimer’s development
Findings of a study by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that increasing expression of a gene known as ABCC1 could not only reduce the deposition of a hard plaque in the brain that leads to Alzheimer’s disease, but might also prevent or delay this memory-robbing disease from developing.
ABCC1, also known as MRP1, has previously been shown in laboratory models to remove a plaque-forming protein known as amyloid beta (Abeta) from specialized endothelial cells that surround and protect the brain and cerebral spinal cord. Building on previous studies, TGen conducted a series of pre-clinical genomic laboratory experiments. Results suggest that ABCC1 not only could export Abeta out of the brain, but that increasing the expression of ABCC1 could reduce Abeta production, thus preventing, or delaying, the onset of Alzheimer’s.
The findings were published in the scientific journal Biology Open.
“Much work remains toward developing a drug that slows the development of or prevents Alzheimer’s disease, but our findings suggest that targeting ABCC1 offers a promising path that could eventually lead to effective therapeutics,” said Wayne Jepsen, a Postdoctoral Fellow in TGen’s Neurogenomics Division, and the study’s lead author.
Alzheimer’s disease is the sixth leading cause of death in the U.S., annually killing more than 120,000 people. There is no treatment that can effectively prevent or slow this disease. An estimated 5.8 million Americans age 65 or older have Alzheimer’s, and that number is expected to more than double over the next 30 years.
Symptoms of Alzheimer’s include: memory loss; difficulty learning new things and problems coping with new situations; difficulty with language and problems with reading, writing and working with numbers; difficulty organizing thoughts and thinking logically; and a shortened attention span.
ABCC1 is an Alzheimer’s drug target
TGen’s study results suggest that ABCC1 is a valid drug target for Alzheimer’s because of the multiple ways the gene influences Abeta; not only potentially exporting it from the brain, but also in the way it modulates cellular processes involving amyloid precursor protein (APP), which is abundant in the brain and can be cut up into smaller pieces via the alpha- or beta-secretase pathways.
The alpha-secretase pathway is associated with the development and protection of neurons, which are the functioning cells of the brain and central nervous system. The resulting soluble APP alpha peptide is also associated with memory formation and a process called synaptic plasticity, in which the synapses that connect neurons and allow them to communicate are able to change and adapt to new information.
The beta-secretase pathway leads to the formation of Abeta, a peptide that accumulates to form amyloid plaques, which along with neurofibrillary tangles are the two pathological hallmarks that define Alzheimer’s. Scientists have hypothesized that decreasing Abeta production could slow the progression of Alzheimer’s.
TGen’s experiments indicated that: ABCC1 modulates APP processing away from the formation of amyloid; confirms previous reports that ABCC1 exports Abeta from the inside of cells to the outside of cells; and that thiethylperazine, a drug long used to ease nausea and vomiting, increases ABCC1 transport activity.
“Compounds that can dramatically increase ABCC1 transport activity, or that can increase ABCC1 expression, may prove to be viable drugs for the treatment or prevention of Alzheimer’s disease by not only increasing clearance of Abeta from the brain, but also by reducing the amount of Abeta that is produced,” said Matt Huentelman, Ph.D., TGen Professor of Neurogenomics, and the study’s senior author.
“Interestingly, due to the historical focus in cancer research on finding ABCC1 inhibiting drugs, we are betting that there are already drugs out there that are known to have an opposite ABCC1-activating effect, and our data suggest that such drugs should be examined for anti-Alzheimer’s disease activity,” Dr. Huentelman said.
Dr. Todd Levine, a neurologist at HonorHealth and an adjunct faculty member at TGen who has reviewed the study but is not an author, said he believes the focus on ABCC1 is a potentially important new avenue of Alzheimer’s research: “While it is still early days, the authors of this study present a compelling case for further investigation of ABCC1 as a potential target for new therapeutics against this devastating disease for which better treatments are urgently needed.”
More from: Translational Genomics Research Institute
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Protein found in brain linked to frontotemporal dementia
An international team of researchers has identified a protein found in the brains of people with frontotemporal dementia (FTD), discovering a new target for potential treatments for the disease.
- AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio
KEY TAKEAWAYS AbbVie plans to acquire Cerevel for $8.7 billion at $45 per share.The deal is expected to close in mid-2024.Through Cerevel, AbbVie will increase its line of treatments for psychiatric ...
- Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is ...
- AbbVie Buys Drugmaker Cerevel Therapeutics For $8.7 Billion
U.S. pharmaceutical giant AbbVie (ABBV) is acquiring neuroscience drugmaker Cerevel Therapeutics (CERE) for $8.7 billion U.S. AbbVie has agreed to pay $45 U.S. for each share of Cerevel and plans to ...
- Alzheimer’s Treatment, Care Lacking for People With Down Syndrome Despite Great Need
Alzheimer’s disease is now the leading cause of death for people living with Down syndrome over the age of 35, and yet, recent drug trials and treatments ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”Alzheimer’s therapeutics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease
The US FDA has accepted Alpha Cognition’s new drug application (NDA) for ALPHA-1062 to treat mild-to-moderate Alzheimer’s disease.
- Study Reveals Plant-Based Diets In China, Japan & India Linked To Lower Alzheimer's Risk
Uncover the link between plant-based diets and Alzheimer's risk reduction in China, Japan, and India. Learn how traditional diets contrast with the Western diet and explore key insights into ...
- Alzheimer’s and Caregivers’ Support Group to meet Dec. 12
The Alzheimer’s and Caregivers’ Support Group will meet Tuesday, Dec. 12, from 7-8 p.m., at Covenant United Methodist Church, 44 W. Main St., Lock Haven. The meeting place has convenient parking next ...
- Serotonin loss may contribute to cognitive decline in the early stages of Alzheimer's disease
Comparing PET scans of more than 90 adults with and without mild cognitive impairment (MCI), researchers say relatively lower levels of the so-called 'happiness' chemical, serotonin, in parts of the ...
- Light therapy may improve symptoms of Alzheimer's disease
Light therapy leads to significant improvements in sleep and psycho-behavioral symptoms for patients with Alzheimer's disease, according to a new study. Light therapy leads to significant improvements ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”Alzheimer’s” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]